In AD, a marker of downstream neurodegeneration, such as NfL, might be useful as a tool for patients’ recruitment in clinical trials on presymptomatic subjects, as well as outcome measures to verify the potential in disease course modification along with the presymptomatic phase. Here, NEFL is linked to Alzheimer disease.